While TP53, encoded by the typical antioncogene P53, is recently reported to be involved in the HIF1alpha/USP2/TP53 axis to promote hypoxia-induced HCC stemness [35], in the MiR-30e-3p/MDM2/TP53 axis to influence Sorafenib resistance in HCC [36], and a TP53-associated immune prognostic model for HCC has been developed and validated [37]. The gene discussed is USP2; the disease is hepatocellular carcinoma.